Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2007

View Archived Issues

VioQuest cancer agents progress through early studies

Docetaxel/telatinib combination shows promise in cancer patients

Lorus reports first quarter results for fiscal 2008

HNE scavengers may have potential in AD

Shire licenses Amigal, Plicera and AT-2220 from Amicus for markets outside of the U.S.

Preliminary study results show FG-4592 well tolerated in CKD anemia

Ferric carboxymaltose injection shows promise in non-dialysis-dependent CKD anemia

Recent developments for Pharmaxis' Bronchitol and Aridol

Post hoc analyses of IDEAL, SPARCL studies show additional benefits of atorvastatin

Phase I study results for ARC-1779 in healthy volunteers available

LY-518674 increases apo A-I production but not HDL cholesterol in metabolic syndrome patients

Phoqus presents update on clinical trial program for Chronocort

TB Alliance conducts clinical trials on moxifloxacin and PA-824 for TB

Santhera initiates FJORD clinical trial of JP-1730 for dyskinesia in Parkinson's disease

Pharmexa reports positive preliminary results from the HVTN 064 phase I trial of EP-1043

Antisense initiates collaborative research program to examine ATL-1101 for prostate cancer

Vivus initiates EQUIP phase III trial of Qnexa in morbidly obese patients

Seattle Genetics initiates phase IIb clinical trial of SGN-33 for acute myeloid leukemia

Expression Genetics receives grant from the National Cancer Institute to develop EGEN-001

Elite concludes special protocol assessment with FDA for phase III trial of ELI-216

KeyNeurotek initiates phase I study of cannabinoid receptor agonist KN-38-7271 for stroke

Santhera presents an update on its clinical development portfolio

FDA accepts Akesis' IND application for phase IIa study of AKP-020 for type 2 diabetes

AtheroGenics discontinuing 300 mg dose of AGI-1067 in ANDES trial

FDA requests additional data for Synvisc-One marketing application

Short-acting sedative-hypnotic presented at Neuroscience meeting

First marketing authorization application submitted for Advexin

Na+ and Ca2+ channel-blocking antiepileptic with a promising pharmacological profile

Recent Tibotec and Pfizer patents report new therapeutic agents for HIV infection

Novel agents for cardiovascular disorders disclosed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...